351 related articles for article (PubMed ID: 15305906)
21. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
Renwick W; Pettengell R; Green M
BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
[TBL] [Abstract][Full Text] [Related]
22. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2011 Apr; 78(1):17-23. PubMed ID: 20227290
[TBL] [Abstract][Full Text] [Related]
23. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
24. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
25. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
26. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
[TBL] [Abstract][Full Text] [Related]
27. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
28. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
29. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Biganzoli L; Untch M; Skacel T; Pico JL
Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
[TBL] [Abstract][Full Text] [Related]
30. Review: Drug-induced neutropenia--pathophysiology, clinical features, and management.
Bhatt V; Saleem A
Ann Clin Lab Sci; 2004; 34(2):131-7. PubMed ID: 15228223
[TBL] [Abstract][Full Text] [Related]
31. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
32. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
33. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim.
Ng JH; Ang XY; Tan SH; Tao M; Lim ST; Chan A
Acta Haematol; 2011; 125(3):107-14. PubMed ID: 21109731
[TBL] [Abstract][Full Text] [Related]
34. Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
Lüftner D; Possinger K
Onkologie; 2005 Nov; 28(11):595-602. PubMed ID: 16249646
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
36. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
[TBL] [Abstract][Full Text] [Related]
37. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
Schuman SI; Lambrou N; Robson K; Glück S; Myriounis N; Pearson JM; Lucci JA
J Support Oncol; 2009; 7(6):225-8. PubMed ID: 20380330
[TBL] [Abstract][Full Text] [Related]
38. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
39. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
Rajan SS; Lyman GH; Stearns SC; Carpenter WR
Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support.
Brugger W; Bacon P; Lawrinson S; Romieu G
Crit Rev Oncol Hematol; 2009 Dec; 72(3):265-9. PubMed ID: 19596586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
